The resulting ADC 59, in which the antibody was trastuzumab, presented a well-defined DAR of 4 and displayed excellent stability properties and antitumor activities against HER2 expressing cancer cells [115] (Scheme 7A). This evidence concerns the gene ERBB2 and cancer.